Category: Markets
Published: 2026-08-17T16:41:18.000Z
Vogenx, Inc., a clinical-stage biopharmaceutical company, successfully completed an $81.3 million initial public offering on August 13, 2026, with its shares trading on the Nasdaq Capital Market under the ticker "VOGX" since August 12, 2026. The IPO, managed by JonesTrading, involved the sale of 6,250,000 shares at $13.00 each, at the high end of the proposed range. The proceeds will be used to advance therapeutics for diseases related to human metabolism dysfunction, such as post-bariatric hypoglycemia and gastroparesis.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.